209 related articles for article (PubMed ID: 36959160)
1. An Overview of CDK Enzyme Inhibitors in Cancer Therapy.
Mounika P; Gurupadayya B; Kumar HY; Namitha B
Curr Cancer Drug Targets; 2023; 23(8):603-619. PubMed ID: 36959160
[TBL] [Abstract][Full Text] [Related]
2. CDK inhibitors in cancer therapy, an overview of recent development.
Zhang M; Zhang L; Hei R; Li X; Cai H; Wu X; Zheng Q; Cai C
Am J Cancer Res; 2021; 11(5):1913-1935. PubMed ID: 34094661
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
4. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
Bose P; Simmons GL; Grant S
Expert Opin Investig Drugs; 2013 Jun; 22(6):723-38. PubMed ID: 23647051
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
Susanti NMP; Tjahjono DH
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361615
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
8. Emerging drug profile: cyclin-dependent kinase inhibitors.
Blachly JS; Byrd JC
Leuk Lymphoma; 2013 Oct; 54(10):2133-43. PubMed ID: 23488658
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Blachly JS; Byrd JC; Grever M
Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
[TBL] [Abstract][Full Text] [Related]
10. Novel small molecule cyclin-dependent kinases modulators in human clinical trials.
Senderowicz AM
Cancer Biol Ther; 2003; 2(4 Suppl 1):S84-95. PubMed ID: 14508085
[TBL] [Abstract][Full Text] [Related]
11. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
[TBL] [Abstract][Full Text] [Related]
12. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.
Vermeulen K; Van Bockstaele DR; Berneman ZN
Cell Prolif; 2003 Jun; 36(3):131-49. PubMed ID: 12814430
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent kinase inhibitors as anticancer drugs.
Krystof V; Uldrijan S
Curr Drug Targets; 2010 Mar; 11(3):291-302. PubMed ID: 20210754
[TBL] [Abstract][Full Text] [Related]
14. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
[TBL] [Abstract][Full Text] [Related]
15. Molecules inducing specific cyclin-dependent kinase degradation and their possible use in cancer therapy.
Zheng M; Zhang XY; Chen W; Xia F; Yang H; Yuan K; Yang P
Future Med Chem; 2024 Feb; 16(4):369-388. PubMed ID: 38288571
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in CDK inhibitors for cancer therapy.
Heptinstall AB; Adiyasa I; Cano C; Hardcastle IR
Future Med Chem; 2018 Jun; 10(11):1369-1388. PubMed ID: 29846081
[TBL] [Abstract][Full Text] [Related]
17. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
Wesierska-Gadek J; Schmid G
Expert Opin Investig Drugs; 2006 Jan; 15(1):23-38. PubMed ID: 16370931
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase modulators and cancer therapy.
Gallorini M; Cataldi A; di Giacomo V
BioDrugs; 2012 Dec; 26(6):377-91. PubMed ID: 22928661
[TBL] [Abstract][Full Text] [Related]
19. Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.
Xie Z; Hou S; Yang X; Duan Y; Han J; Wang Q; Liao C
J Med Chem; 2022 May; 65(9):6356-6389. PubMed ID: 35235745
[TBL] [Abstract][Full Text] [Related]
20. Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor.
Kobayashi M; Takahashi-Suzuki I; Shimomura T; Iwasawa Y; Hirai H
Invest New Drugs; 2011 Oct; 29(5):921-31. PubMed ID: 20524038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]